1
|
Stein J, Klümper N, Zöhrer P, Büttner T, Krausewitz P, Ritter M, Kristiansen G, Toma M, Ellinger J, Cox A. Ring Finger Protein 34 (RNF34) as a Prognostic Biomarker for Clear Cell Renal Cell Carcinoma. Cureus 2024; 16:e53038. [PMID: 38410284 PMCID: PMC10895560 DOI: 10.7759/cureus.53038] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/26/2024] [Indexed: 02/28/2024] Open
Abstract
INTRODUCTION Ring finger proteins play pivotal roles in diverse cellular processes and are implicated in contribution to cancer. Ring finger protein 34 (RNF34) has antiapoptotic and oncogenic properties. RNF34 is upregulated during carcinogenesis and tumor progression in the colorectal adenoma-carcinoma sequence and was already described to mediate chemoresistance. In clear cell renal cell carcinoma (ccRCC), however, the role and expression patterns of RNF34 are unknown. METHODS First, we investigated the association of RNF34 mRNA expression with clinicopathological parameters and survival using data obtained from The Cancer Genome Atlas (TCGA) ccRCC cohort (N = 533). To assess RNA34 protein expression, we performed immunohistochemical (IHC) staining of an established ccRCC cohort (University of Bonn) in a tissue microarray (TMA) format. This validation cohort contains 109 primary ccRCC samples. IHC data were associated with clinicopathological parameters and overall survival (Kaplan-Meier analysis). Adjustment for covariables was done using the Cox regression model. RESULTS RNF34 expression is correlated with adverse clinicopathological parameters. Survival analysis revealed an association between RNF34 expression and shortened survival. Cox regression analysis confirmed RNF34 expression as an independent prognostic parameter. CONCLUSION Our study provides evidence for RNF34 as a prognostic biomarker in ccRCC and points toward a major role of this protein in renal cell carcinoma carcinogenesis.
Collapse
Affiliation(s)
- Johannes Stein
- Urology, University Hospital Bonn, University of Bonn, Bonn, DEU
- Center for Integrated Oncology Cologne/Bonn, University Hospital Bonn, University of Bonn, Bonn, DEU
| | - Niklas Klümper
- Urology, University Hospital Bonn, University of Bonn, Bonn, DEU
- Center for Integrated Oncology Cologne/Bonn, University Hospital Bonn, University of Bonn, Bonn, DEU
| | - Pirmin Zöhrer
- Urology, University Hospital Bonn, University of Bonn, Bonn, DEU
- Center for Integrated Oncology Cologne/Bonn, University Hospital Bonn, University of Bonn, Bonn, DEU
| | - Thomas Büttner
- Urology, University Hospital Bonn, University of Bonn, Bonn, DEU
- Center for Integrated Oncology Cologne/Bonn, University Hospital Bonn, University of Bonn, Bonn, DEU
| | - Philipp Krausewitz
- Urology, University Hospital Bonn, University of Bonn, Bonn, DEU
- Center for Integrated Oncology Cologne/Bonn, University Hospital Bonn, University of Bonn, Bonn, DEU
| | - Manuel Ritter
- Urology, University Hospital Bonn, University of Bonn, Bonn, DEU
- Center for Integrated Oncology Cologne/Bonn, University Hospital Bonn, University of Bonn, Bonn, DEU
| | - Glen Kristiansen
- Pathology, University Hospital Bonn, University of Bonn, Bonn, DEU
- Center for Integrated Oncology Cologne/Bonn, University Hospital Bonn, University of Bonn, Bonn, DEU
| | - Marieta Toma
- Pathology, University Hospital Bonn, University of Bonn, Bonn, DEU
- Center for Integrated Oncology Cologne/Bonn, University Hospital Bonn, University of Bonn, Bonn, DEU
| | - Jörg Ellinger
- Urology, University Hospital Bonn, University of Bonn, Bonn, DEU
- Center for Integrated Oncology Cologne/Bonn, University Hospital Bonn, University of Bonn, Bonn, DEU
| | - Alexander Cox
- Urology, University Hospital Bonn, University of Bonn, Bonn, DEU
- Center for Integrated Oncology Cologne/Bonn, University Hospital Bonn, University of Bonn, Bonn, DEU
| |
Collapse
|
2
|
Jaekel AK, Watzek J, Nielsen J, Butscher AL, Zöhrer P, Schmitz F, Kirschner-Hermanns RKM, Knüpfer SC. Neurogenic Lower Urinary Tract Symptoms, Fatigue, and Depression-Are There Correlations in Persons with Multiple Sclerosis? Biomedicines 2023; 11:2193. [PMID: 37626690 PMCID: PMC10452515 DOI: 10.3390/biomedicines11082193] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2023] [Revised: 07/28/2023] [Accepted: 08/01/2023] [Indexed: 08/27/2023] Open
Abstract
The symptoms of multiple sclerosis (MS) frequently include fatigue, depression, and neurogenic lower urinary tract symptoms (LUTS), causing severe burdens on affected individuals. The relationships between these symptoms have not been intensively researched and there are no studies on the detailed influence of the different neurogenic LUTS. We aimed to investigate the relationships between fatigue, depression, and neurogenic LUTS as recorded in bladder diaries by persons with MS. We analyzed the bladder diaries of 274 people and their scores on the Fatigue Scale for Motor and Cognitive Functions and the Centre for Epidemiologic Studies Depression Scale (German version). The neurogenic LUTS were defined as urgency, reduced voided volume, increased standardized voiding frequency, nocturia, and urinary incontinence. Those suffering from incontinence, nocturia, reduced voided volume, or urgency had higher fatigue scores compared to those without these symptoms. Those with nocturia showed significantly higher scores for depression. The severity of urgency and voided volume had the greatest effect on the severity of individuals' fatigue and depression levels. With increasing urgency, the risk of clinically significant fatigue and depression was expected to increase. Urgency and voided volume correlated most with fatigue and depression. A prospective longitudinal study investigating fatigue/depression after the successful treatment of neurogenic LUTS is needed to clarify causality and offer possible treatment options for fatigue and depression.
Collapse
Affiliation(s)
- Anke K. Jaekel
- Department of Neuro-Urology, Clinic for Urology, University Hospital Bonn, 53127 Bonn, Germany
- Department of Neuro-Urology, Johanniter Neurological Rehabilitation Center Godeshoehe GmbH, 53177 Bonn, Germany
| | - Julius Watzek
- Department of Neuro-Urology, Clinic for Urology, University Hospital Bonn, 53127 Bonn, Germany
| | - Jörn Nielsen
- Department of Cognitive Rehabilitation, Neurological Rehabilitation Center Godeshoehe GmbH, 53177 Bonn, Germany
- Department of Medical Psychology | Neuropsychology and Gender Studies, Center for Neuropsychological Diagnostics and Intervention (CeNDI), Faculty of Medicine and University Hospital Cologne, University of Cologne, 50937 Cologne, Germany
| | - Anna-Lena Butscher
- Department of Neuro-Urology, Johanniter Neurological Rehabilitation Center Godeshoehe GmbH, 53177 Bonn, Germany
| | - Pirmin Zöhrer
- Department of Neuro-Urology, Clinic for Urology, University Hospital Bonn, 53127 Bonn, Germany
| | - Franziska Schmitz
- Department of Neuro-Urology, Clinic for Urology, University Hospital Bonn, 53127 Bonn, Germany
| | - Ruth K. M. Kirschner-Hermanns
- Department of Neuro-Urology, Clinic for Urology, University Hospital Bonn, 53127 Bonn, Germany
- Department of Neuro-Urology, Johanniter Neurological Rehabilitation Center Godeshoehe GmbH, 53177 Bonn, Germany
| | - Stephanie C. Knüpfer
- Department of Neuro-Urology, Clinic for Urology, University Hospital Bonn, 53127 Bonn, Germany
| |
Collapse
|
3
|
Vauth F, Zöhrer P, Girtner F, Rösch WH, Hofmann A. Open Pyeloplasty in Infants under 1 Year-Proven or Meaningless? Children (Basel) 2023; 10:children10020257. [PMID: 36832385 PMCID: PMC9955854 DOI: 10.3390/children10020257] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 12/31/2022] [Revised: 01/28/2023] [Accepted: 01/29/2023] [Indexed: 02/01/2023]
Abstract
The use of minimally invasive surgery (MIS) to treat ureteropelvic junction obstruction (UPJO) in children has significantly increased. Nowadays, open pyeloplasty (OP) seems to lose importance. The aim of this study is to evaluate the safety and efficacy of OP in infants < 1 year. Medical records of patients < 1 year with UPJO who had undergone retroperitoneal OP (January 2008-February 2022) at our institution were retrospectively analyzed. Included patients were operated on according to a modified Anderson-Hynes technique. All clinical, operative, and postoperative (1 month-5 years' follow-up) data were collected. Additionally, a nonvalidated questionnaire was sent to the patients/parents. A total of 162 infants (124 boys) met the inclusion criteria. The median age at surgery was 3 months (range: 0-11 months). The median operation time was 106 min (range: 63-198 min). None of the patients had severe surgical complication (Clavien-Dindo > 3). The nonvalidated questionnaire showed a high impact of quality of life. Follow-up was in median 30.5 months (0-162 months). OP is still a reliable procedure with good long-term results especially in infants < 1 year of age, which can be performed in a variety of centers.
Collapse
|